Abdul Mannan: APTT Mixing Studies Confuse a Lot of People
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared on LinkedIn:
”APTT mixing studies confuse a lot of people.
Let me show you why the incubated step matters.
Factor VIII is thermally labile. At 37°C, it naturally decays over 1-2 hours.
This isn’t pathology—it’s normal biology.
But here’s the trick: this can look exactly like a time-dependent inhibitor if you’re not careful.
The solution? Run parallel tests.
Here’s what you need to know:
- Test both immediate AND incubated samples (at 2 hours)
- Compare patient plasma alone vs 1:1 mix with normal pooled plasma
- Normal thermal decay: slight drift in both NPP and 1:1 mix
- Time-dependent inhibitor: the 1:1 mix prolongs MORE than NPP control
- Golden rule: If Δ(1:1 Mix) > Δ(NPP Control), think inhibitor
The pattern tells the story.
Normal FVIII lability shows similar small shifts in both tubes.
A true inhibitor shows clearly more prolongation in the mix than the control—it’s time AND temperature dependent, not just thermal drift.
Pro tip: Always use properly buffered conditions (Nijmegen-modified) for stability.
Thaw plasma promptly at 37°C and test without delay for routine assays. If you’re uncertain, measure
FVIII:C before and after incubation.
What’s the most challenging APTT mixing study pattern you’ve interpreted recently?”

Stay updated with Hemostasis Today.
-
May 22, 2026, 15:02Robert Brodsky: Can You Stop Thrombosis and Treat CAPS Without Anticoagulation?
-
May 22, 2026, 14:50Eric Topol: New Nature Editorial on the Limits and Promise of AI Scientists
-
May 22, 2026, 14:40Harry Spoelstra: Omicron COVID-19 and Coronary Thrombosis Without Atherosclerosis
-
May 22, 2026, 14:21Clinical Challenges in Thrombosis III – Thrombosis Canada
-
May 22, 2026, 14:03Wolfgang Miesbach: Exploring the Role of Micronutrients in Healthy Longevity
-
May 22, 2026, 13:53Masoabi Sefojane: The Structural Invisibility of Bleeding Disorders in the Global South
-
May 22, 2026, 13:41Ney Carter Borges: New Trial Highlights IVL as Effective Strategy for Calcified Coronary Lesions
-
May 22, 2026, 13:36Ajay Samkaria։ A Compatible Crossmatch Does Not Always Mean Complete Safety
-
May 22, 2026, 13:31Mariam Swidan: Why Hemolysis Severity Matters in G6PD Deficiency